Clinical Trials Logo

Head Lice Infestation clinical trials

View clinical trials related to Head Lice Infestation.

Filter by:
  • None
  • Page 1

NCT ID: NCT06057506 Recruiting - Clinical trials for Head Lice Infestation

Comparative Study for the Evaluation of Two Medical Devices on the Treatment of Head Lice Infestation

Start date: August 21, 2023
Phase: N/A
Study type: Interventional

Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation. The test items have been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimative convenience in use - making treatment of head lice infestation easy, and effective in few minutes. The main objective of this clinical study is to confirm the efficacy on head lice treatment of two Medical Devices, already in market.

NCT ID: NCT04878276 Recruiting - Pediculosis Capitis Clinical Trials

Comparative Head Lice Therapy With Dimet 5® vs. Hedrin® Once

VEKODIH
Start date: May 17, 2021
Phase:
Study type: Observational

Randomized, investigator-blinded, controlled, multicenter comparative study on the treatment of acute head lice infestation in children with 2 dimeticone preparations with different application times and compositions: Dimet 5® (100% dimeticone) versus Hedrin® Once Liquid Gel (4% dimeticone + nerolidol) with treatment success assessment via freedom from infestation of live head lice at final examination at V2, i.e. day 19 after first treatment.

NCT ID: NCT02097485 Completed - Clinical trials for Head Lice Infestation

Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The purpose of the study was to evaluate ovicidal efficacy of a single application of abametapir lotion 0.74% w/w intended for the treatment of head lice.

NCT ID: NCT02062060 Completed - Clinical trials for Head Lice Infestation

Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

Start date: February 2014
Phase: Phase 3
Study type: Interventional

Purpose of this study is to evaluate the efficacy of at-home administration of a single application of abametapir lotion 0.74% w/w for the treatment of head lice.

NCT ID: NCT02060903 Completed - Clinical trials for Head Lice Infestation

A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

Start date: February 2014
Phase: Phase 3
Study type: Interventional

The purpose of the study was to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the scalp and hair for 10 minutes at home.

NCT ID: NCT02010333 Completed - Clinical trials for Head Lice Infestation

A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation

Start date: April 2013
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to evaluate safety and tolerability of a single application of Ha44 Gel 0.74% w/w for the treatment of head lice. Secondary purpose is to evaluate PK of Ha44 and benzyl alcohol under conditions of maximal exposure in pediatric population.

NCT ID: NCT01907490 Completed - Clinical trials for Head Lice Infestation

Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability of a single application of Ha44 Gel 0.74% w/v for the treatment of head lice under maximal use conditions. Secondary objective is to evaluate pharmacokinetics of Ha44 and benzyl alcohol (contained in Ha44 vehicle) under maximal use conditions.